XSpray Pharma AB

XSPRAY · Nasdaq Stockholm · Healthcare

12.56SEK +19.4%last day

Price as of 2 October 2026

The price over the past year, with dividends: −79.1%

Performance

1 month

+24.9%

1 year

−79.1%

3 years, per year

−32.1%

5 years, per year

−37.1%

Largest fall, 3 years

−89.6%

Below the peak now

−95.1%

Volatility, 1 year

90.9%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

0.9

Dividend yield

0.0%

Return on equity

−25.0%

Net margin

−158.4%

Market value

57 m USD

Quality, value and trend

Where XSpray Pharma stands against every Nordic stock today. 100 is best.

Quality73

Profitability and a sound balance sheet over time. Better than 73% of Nordic stocks.

Value19

The price measured against earnings, assets and cash flow. Better than 19% of Nordic stocks.

Trend5

The price development over the past year. Better than 5% of Nordic stocks.

Combined17

Quality, value and trend together. Better than 17% of Nordic stocks.

About XSpray Pharma

XSpray Pharma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 24 employees.

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partnership agreements with EVERSANA for the commercialization of Dasynoc.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis